ReviewFrontiers in neurology2026
Non-invasive neuromodulation for drug-resistant epilepsy: a contemporary structured review of mechanisms, clinical evidence and future directions.
Review in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-resistant epilepsy (DRE) affects nearly one-third of people with epilepsy and remains a major cause of disability despite continued advances in antiseizure medications and surgical therapies. For patients who are not candidates for resective surgery or invasive neuromodulation, non-invasive neuromodulation (NIN) has emerged as a promising strategy to modulate epileptic networks while avoiding the risks associated with implanted devices. This structured narrative review examines current evidence across the principal NIN modalities, including repetitive transcranial magnetic stimulation (rTMS), transcranial electrical stimulation (transcranial direct current (tDCS), alternating current, and temporal interference stimulation), transcutaneous vagus nerve stimulation, trigeminal nerve stimulation, and transcranial focused ultrasound. We integrate current knowledge on mechanisms of action, clinical efficacy, safety, and practical considerations while highlighting recent advances that may shape future clinical implementation. Available evidence indicates that low-frequency rTMS and cathodal tDCS provide the most consistent reductions in seizure frequency and interictal epileptiform discharges, particularly in focal DRE. Transcutaneous vagus nerve stimulation has shown encouraging results with an excellent safety profile, whereas focused ultrasound, trigeminal nerve stimulation, and temporal interference stimulation remain investigational and require further clinical validation. Across modalities, interpretation of current evidence is limited by heterogeneous stimulation protocols, small study populations, and variable outcome measures. Emerging approaches, including individualized targeting, connectome-guided stimulation, computational modeling, neurophysiological biomarkers, and adaptive closed-loop neuromodulation, are expected to improve treatment precision and patient selection. Although high-quality multicenter randomized trials remain necessary, current evidence supports NIN as an increasingly relevant component of personalized epilepsy care and a promising avenue for expanding therapeutic options in DRE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.